Board Member
Dianthus Therapeutics, Inc. (DNTH)Equibles does not estimate personal net worth.
Get an email with a short summary when Dianthus Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DNTH alertsMarino Garcia is recorded as Board Member at Dianthus Therapeutics, Inc. (DNTH) since January 1, 2021 and CEO at Dianthus Therapeutics, Inc. (DNTH). The newest filing on record that lists Marino Garcia as CEO and Board Member at Dianthus Therapeutics, Inc. (DNTH) is dated April 9, 2026. Dianthus Therapeutics, Inc. reported in an 8-K filed September 12, 2023 that Marino Garcia was appointed President and Chief Executive Officer and principal executive officer, effective September 11, 2023. Dianthus Therapeutics, Inc. reported in an 8-K filed September 12, 2023 that Marino Garcia was appointed Board of Directors, effective September 11, 2023. The proxy statement of Dianthus Therapeutics, Inc. reports total compensation of $10,614,702 for Marino Garcia in fiscal 2025, including a base salary of $630,000. Disclosed compensation is on record for 3 fiscal years. Marino Garcia has spoken on 1 earnings call and 2 other investor events across 1 company, most recently for Dianthus Therapeutics, Inc. on September 9, 2026. Dianthus Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dianthus Therapeutics, Inc. includes Alison F. Lawton (Chairman), Leon O. Moulder, Jr. (Chairman and Board Member), Ryan Savitz (CFO) and 7 others.
“On September 11, 2023, the Board of Directors appointed Marino Garcia as the Company's President and Chief Executive Officer and principal executive officer, Ryan Savitz as the Company's Treasurer and Chief Financial Officer and principal financial officer and Edward Carr as the Company's Chief Accounting Officer and principal accounting officer.”
“In accordance with the Merger Agreement, immediately after the closing of the Merger on September 11, 2023, the size of the Board of Directors was fixed at eight members, consisting of two members designated by the Company, who are Alison F. Lawton and Anne McGeorge, and six members designated by OpCo, who are Marino Garcia, Leon O. Moulder, Jr., Tomas Kiselak, Lei Meng, Paula Soteropoulos and Jonathan Violin, Ph.D.”
“Thank you, Sam, and thank you to Citi for allowing us to be here today and for hosting this webinar.”
“So Dianthus Therapeutics, we are building a really exciting autoimmune company focused on rare diseases. Our first program is a very potent classical pathway inhibitor, an active C1S inhibitor called ClasiproBard, where we are taking it into building a nice sort of neurology neuromuscular franchise with it.”
“Thank you, operator. good morning everyone and thank you for joining us today earlier this morning we issued a press release with our early go decision for the interim responder analysis for a captivate trial and CIDP and we're thrilled to share with you more today on this call this earlier than anticipated…”
2021-01-01–present
Last confirmed April 9, 2026
Start not stated–present
Last confirmed April 9, 2026
Biotechnology · Healthcare
CEO, Board Member
2021-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Dianthus Therapeutics, Inc. (DNTH) | President and Chief Executive Officer | $630,000 | $10,614,702 |
| 2024 | Dianthus Therapeutics, Inc. (DNTH) | President and Chief Executive Officer | $600,000 | $8,843,300 |
| 2023 | Dianthus Therapeutics, Inc. (DNTH) | President and Chief Executive Officer | $174,863 | $496,022 |
